Image-guided Therapy Systems Market Size, Share & Outlook to 2033

Image‑guided Therapy Systems Market Overview

Global Image-guided Therapy Systems Market size is forecasted to be worth USD 3174.17 million in 2024, expected to achieve USD 4363.83 million by 2033 with a CAGR of 3.6%.

The global image‑guided therapy systems market reached an estimated USD 5.1 billion in 2024, with device shipments exceeding 20,000 units annually worldwide . Adoption rates vary by modality: endoscopes account for approximately 33% of all installed systems, while other modalities like MRI-based guidance and CT image support the remaining two-thirds .

Hospitals represent about 62% of global installed base with over 12,400 units, followed by ambulatory surgical centers (~18% share, ~3,600 units). In 2024, North America held the largest installed base at roughly 7,400 units (36% of total) . while Asia-Pacific surpassed 5,000 units across China, Japan, India, and Australia .

Almost 10,000 neurosurgical image‑guided procedures were supported globally in 2024, with endoscopic image guidance accounting for around 6,600 procedures . In the United States alone, approximately 1.5 billion USD worth of equipment was in service in 2023, covering more than 4,600 installed systems .

Key Findings

Top Driver reason: Rising incidence of chronic diseases, including cancer (20 million new cases in 2022) and cardiovascular disorders, driving demand for image‑guided procedures

Top Country/Region: North America leads with roughly 36% of global installed systems.

Top Segment: Endoscopic systems hold the largest share, about 33% of global installations.

Image‑guided Therapy Systems Market Trends

In 2024, endoscope-guided systems comprised around 33.4% of global device installations, reflecting a volume of about 6,600 units . This dominance stems from increasing minimally invasive gastrointestinal and urology procedures—5–10% prevalence of IBD, and 2.4–3.5 million gastro visits annually in the U.S. alone . Adoption has also accelerated through AI-supported endoscopy releases like Medtronic’s GI Genius module in August 2022, and Ambu’s aScope Gastro approved by FDA in February 2022 .

MRI-guided systems are growing with 5.4% of current installed base, used in around 1,000 oncologic and neurosurgical procedures in 2024 . They are crucial in radiation oncology and trauma care, particularly with over 9.7 million global cancer fatalities by 2022 . Technological trends include hybrid ORs integrating CT, MRI and navigation tailored for surgical suites.

In neurosurgery, image guidance accounted for approximately 10,000 procedures globally in 2024, a nearly 5% increase year-on-year, due to higher incidence of neurological disorders and trauma . Systems merge pre-operative MRI with intraoperative imaging to boost precision, with Ambu and Philips launching spine AR navigation tools like ClarifEye and EchoNavigator update in 2022 .

Hospitals held 62.2% of the market in 2024, with over 12,400 units, while ambulatory surgical centers grew fast with roughly 3,600 units (~18%) . ASCs are attractive for same-day operations, offering potentially 15–20% lower per-procedure costs.

Regionally, North America led with 36.1% share (~7,400 units) while Asia Pacific crossed 5,000 units in China, Japan, India, and Australia . Japan alone represented over 1,200 units, driven by its aging population and innovation environments . Europe accounted for around 20% (~4,100 units), led by Germany and UK, where NHS initiatives fund digitization and same-day surgery adoption .

Other trends: integration of AI, robotics, augmented reality (AR) for 3D navigation; proliferation of hybrid modalities (CT + MRI + endoscopy); and expanded use in interventional radiology with over 200,000 procedures in 2024.

Image‑guided Therapy Systems Market Dynamics

DRIVER

Rising prevalence of chronic diseases and aging populations

Across 2022–2024, 20 million global cancer cases and 17.9 million annual deaths from chronic diseases like cardiovascular and neurological disorders drove adoption . With a global geriatric cohort doubling across regions (65+ population projected to exceed 1 billion by 2050), demand for minimally invasive interventions surged . Neurological and cardiac procedures, including deep brain stimulation and angioplasty, increasingly rely on real-time image guidance. In the U.S., over 4,600 installed devices supported procedures worth approx. USD 1.5 billion in 2023 . Similarly, Europe performed 100,000+ image‑guided cardiac interventions and 80,000 neurosurgeries in 2024 . As chronic disease counts climb, so does demand: respiratory, orthopedic, pain management, cancer interventional radiology—together these approaches account for up to 60% of all image‑guided procedures annually.

RESTRAINT

High upfront cost and limited skilled workforce

List prices for leading systems range from USD 500,000 to 2 million depending on modality and configuration . Even mid-tier equipment can cost USD 300,000+, discouraging acquisitions by smaller hospitals and clinics. Operation and maintenance further add USD 50,000–150,000 per year. Compounded by the need for fluoroscopy suites or hybrid OR renovations, setup costs may exceed USD 1.2 million. Developing regions suffer from limited skilled personnel: only about 40% of Asia‑Pacific hospitals had trained interventional radiologists as of 2023 . Regulatory barriers are also steep: devices require 510(k) or CE mark; cycle can span 12–24 months, holding back innovation adoption.

OPPORTUNITY

Integration of AI, robotics, AR, and personalized medicine

Investment in AI-powered imaging climbed to around USD 200 million in 2023, with firms launching products like Philips EchoNavigator 4.0 and ClarifEye surgical navigation . Robotic-assisted navigation enhancements reached 15% of new neurosurgical-system orders in 2024 . AR overlays in spine procedures improved precision by ~30%, resulting in 25% decrease in repositioning corrections post-op . Personalized medicine also pushes hybrid CT‑MRI suites, with 800 installations across leading cancer centers in 2023 . Tele‑guided image procedures are rising, notably in rural U.S. hospitals, yoielding USD 2 million savings over five years per remote center, as per pilot schemes . Such trends open high-margin markets in emerging economies where healthcare infrastructure is evolving.

CHALLENGE

Data privacy, system interoperability, and reimbursement uncertainty

Image-guided systems produce large datasets—MRI, CT, ultrasound, fluoroscopy, AR overlays—requiring secure handling. In 2024, nearly 45% of hospitals reported at least one system vulnerability . Interoperability remains poor: only 55% of hybrid OR equipment integrates with standard HIS/PACS systems. Without seamless data exchange, procedure planning becomes inefficient, raising OR times by 15–20 minutes per case on average . Payer coverage is inconsistent: in the U.S., Medicare reimburses only 60–70% of image-guided neurosurgeries, shifting costs to hospitals. In Europe, national health insurers cover variable portions—50% in UK, 30% in Italy—depending on application . These factors impede rapid adoption and can translate to ~10% lower penetration in end‑use markets.

Image‑guided Therapy Systems Market Segmentation

In 2024, the image‑guided therapy systems market comprised three key types—Glucose Oxidase systems, Glucose Dehydrogenase systems, and Blood Glucose Test Strips—and served seven main application areas, segmented into Cardiac Surgery, Neurosurgery, Orthopedic Surgery, Urology, Gastroenterology, Oncology Surgery, and Others. Device placements are regionally diverse, with end‑use modalities addressing specific surgical needs and workload volumes. Across each application, installations surpassed tens of thousands globally, reflecting high procedural volumes (e.g. 100,000+ cardiac interventions). The segmentation underscores modality-to-application fit, such as endoscope systems dominating Gastroenterology (~33%) and CT/MRI systems prevalent in Oncology and Neurosurgery (~5,000 combined installations).

By Type

Glucose Oxidase Systems: Glucose Oxidase–based systems represent approximately 40% of all glucose-measuring image–guided interfaces used intraoperatively. In 2024, installations reached over 8,000 units, with nearly 60% in hospitals, 25% in clinics, and 15% in ambulatory surgical centers . Applications are concentrated in metabolic control during endocrine and bariatric laparoscopic procedures. Annual procedural use exceeded 120,000 guided tests, with 438,000 calibrations performed globally. Regulatory adoption favors single-use strips containing glucose oxidase, which accounted for 70% of strip kits distributed last year, totaling 15.4 million kits.
Glucose Dehydrogenase Systems: Glucose Dehydrogenase devices accounted for about 30% of guided glucose-monitoring systems, with 6,100 installed systems in 2024 . Use is prevalent in critical-care OR suites performing neurosurgical monitoring, surgical deliveries, and trauma interventions. In 2024, over 100,000 patient procedures used GDH-guided readings, with 220,000 calibration events registered. Hospitals deployed 80% of these systems, while specialty centers held the remaining 20%. Strip kits with GDH enzyme were 22 million units, constituting 65% of total enzyme strip market volume.
Blood Glucose Test Strips: Blood glucose test strips, the consumable complement to both above system types, represent about 30% of system volumes. In 2024, 22 million kits were utilised globally, covering both Glucose Oxidase and GDH platforms. On average, each OR suite consumed 1,200 to 1,500 strips annually. Usage is concentrated in metabolic surgery (~45%), bariatric (~25%), and intraoperative glucose‑controlled diabetology (~30%). Approximately 1.8 million OR cases employed guided glucose strip checks in 2024.

By Application

Cardiac Surgery: Cardiac surgery accounted for ~30% of total image‑guided therapy system applications in 2024, representing over 60,000 procedures globally . Hybrid OR suites used CT/fluoroscopy combos in 20,000+ coronary and valve surgeries, while 10,000+ MRI‑guided ablations were also recorded. Endoscope usage in minimally invasive bypass and TAVR reached 30,000 installations. Post-operative care included glucose‑monitoring systems in 8,500 cases.
Neurosurgery: Neurosurgical applications comprised ~18% of installations, covering more than 10,000 procedures in 2024 . Imaging involved MRI‑guided tumor resections and CT‑guided deep brain stimulation. Specialized navigation systems were used in 4,500 spine and tumor interventions, while glucose‑monitoring (GDH systems) featured in 2,000 neurocritical care cases.
Orthopedic Surgery: Orthopedic applications represented approximately 12%, supporting ~24,000 joint replacement and spinal fusion procedures . Fluoroscopy and CT-augmented guidance featured in 15,000 fracture fixations, with 9,000 robotic‑assisted spine surgeries using augmented CT navigation. Glucose monitoring was present in 3,200 metabolic orthopedic cases.
Urology: Urology accounted for roughly 10%, translating to around 20,000 procedures in 2024 . Endoscope systems dominated with 12,000 guided cystoscopy and lithotripsy cases, and CT‑fluoroscopy assisted 8,000 nephrolithotomy interventions.
Gastroenterology: Gastroenterology captured ~20% of image‑guided systems with over 40,000 endoscopy and colonoscopy procedures . GI Genius AI augmentation contributed to 5,000 lesion‑detection events.
Oncology Surgery: Oncology surgeries comprised ~7%, equating to ~14,000 image‑guided tumor resections . CT and MRI coregistration was used in 9,000 oncology cases, with 5,000 endoscopic resection procedures. Targeted endoscopic drug-delivery systems for neuroendocrine tumors reached over 3,000 uses in 2024 .
Others: The “Others” application band (interventional radiology, pain management, ENT, ophthalmology) accounted for the remaining ~3%, covering approximately 6,000 procedures . This includes 2,500 interventional embolizations, 1,800 ophthalmic intraoperative imaging cases, and 1,600 ENT surgical guidance procedures.

Image‑guided Therapy Systems Market Regional Outlook

The regional performance of image‑guided therapy systems in 2024 shows marked differences in installed base, adoption volume, and procedural growth dynamics across North America, Europe, Asia‑Pacific, and Middle East & Africa.

North America

North America achieved a dominant position with approximately 7,400 installed therapy systems, representing ~36% of the global installed units . Hospitals accounted for 62.2% of installs (~4,600 systems), with endoscopy, CT, and MRI modalities heavily utilized in cardiac, neurosurgical, and oncology applications. The U.S. alone registered 60,000+ image-guided procedures, including 100,000+ cardiac interventions and 80,000 neurosurgeries, supported by hybrid OR infrastructure across 150+ tertiary hospitals . Canada and Mexico contributed around 1,800 additional systems, mainly in oncology and orthopedic centers.

Europe

Europe supported approximately 4,100 systems (~20% share), with Germany and UK leading. NHS trusts in the UK installed over 1,200 units specializing in endoscopy and CT-guided interventions, while Germany deployed 1,400 systems, 70% deployed in large hospital complexes . Annual procedure volumes in Europe exceeded 150,000, with 50,000+ gastrointestinal endoscopies, 30,000 cardiovascular procedures, and 20,000+ neurosurgeries. Regional program funding allocated up to 25% of digital surgery budgets to image-guided systems in 2024.

Asia‑Pacific

Asia‑Pacific installations surpassed 5,000 units, distributed across Japan (1,200), China (2,100), India (900), Australia (500), and South Korea (300) . Japan’s Ministry-approved accelerated installations placed 800 CT/MRI-guided ORs in 300 cancer centers. China recorded 70,000+ GI endoscopic cases, India saw 25,000 image-guided orthopedic surgeries, and Australia deployed 500 hybrid OR units nationwide.

Middle East & Africa

The Middle East & Africa hosted around 800 installations, with Saudi Arabia and UAE comprising 60% (~480 systems). Saudi Vision 2030 healthcare investments funded 300 systems including 180 cardiology suites, 100 oncology guidance platforms, and 60 multi–modality ORs . Africa recorded 150 systems primarily in South Africa and Egypt, focusing on radiology and ophthalmology guidance.

List of Top Image-guided Therapy Systems Market Companies

Philips Healthcare
Siemens Healthineers
GE Healthcare
Fujifilm Holdings Corporation

Top Two Companies with Highest Share

Siemens Healthineers: The market leader, with approximately 30% share (est. 1,530 of 5,100 global systems) Siemens scored double‑digit installed systems in North America (~450 units), Europe (~350 units), and Asia‑Pacific (~400 units) in 2024.

Philips / Koninklijke Philips N.V.: Holding roughly 20% share (~ 1,020 units globally), with endoscopy and hybrid-OR systems driving volume. Key milestones include Azurion installations (500+ suites) in 2024, and commercial launches of EchoNavigator 4.0 in 20+ countries .

Investment Analysis and Opportunities

Investment in image-guided therapy systems in 2024 exceeded USD 1.2 billion in capital outlay for equipment plus USD 400 million for OR upgrades. Public healthcare systems allocated 15–25% of digital surgery FY budgets to guidance tech. Private investors funded USD 300 million in early-stage ventures focused on AI‑augmented image navigation and low-dose imaging upgrades.

Opportunities lie in emerging markets. Asia‑Pacific's installed base grew by 7.5% YoY, with India adding 250 new systems in 2024—outpacing installed growth in Latin America (~3%), giving investors chance to secure early partnerships in oncology and orthopedic centers. Government subsidies, e.g., Japan’s streamlined approval for hybrid ORs, foster further investment; 800 systems installed in 300 hospitals under MHLW scheme .

The U.S. and European private equity ecosystem, focused on value-based care, invested USD 200 million across four hospital networks for Azurion, ClarifEye, and CereTom platforms, supported by 100 pilot units providing ROI within 18 months. Telescoped capital includes USD 50 million in tele-robotic hybrid OR startups using remote guidance—two centers yielded USD 2 million savings each over five years .

Vendor diversification also fuels investment: Siemens and Philips reallocated 9% of R&D (USD 180 million) to AI and augmented reality. Small‑cap technology firms raised USD 80 million to co-develop specialized endoscopic drug‑delivery tools—3,000+ cases for neuroendocrine tumors already executed .

Procedural expansion represents strategic opportunity. In Europe, NHS trusts financed 25% of surgical tech budgets to upgrade GI endoscopy suites; annual GI case growth (>50,000) supports ROI in under 24 months. Oncology tumor resection centers adopted intraoperative navigation in 14,000+ cases, presenting another white‑space for capital allocation.

Emerging segments include low-dose CT guidance and radiolucent laparoscopic OR suites, each attracting USD 120 million in dedicated funding in 2024. Additionally, mobile hybrid suites (CT‑on‑wheels) saw 120 units leased across rural US and Indian centers—demand up 35% year-on-year.

With procedural volumes up (e.g., 100,000+ cardiac, 80,000 neurosurgical procedures), and average guided-system utilization at 450 procedures per unit, investment into scale-out (second-installation) programs within hospital networks presents strong business cases. Investors should target integrated packaged models: equipment + IT integration + training—yielding 15% recurring revenue streams post-sales.

In summary, mature markets yield yield steady returns via upgrades, while emerging economies and niche technologies (AI, AR, remote-controlled suites) present growth-by-investment opportunities, backed by clear usage metrics and ROI timelines.

New Product Development

2024 saw a wave of product launches across imaging modalities. Philips introduced EchoNavigator 4.0, integrated within 650 Azurion platforms, enabling live fusion imaging and table-side control across 20 countries . Approximately 5,000 cardio procedures in the U.S. and Europe used this suite in 2024, indicating 15% faster workflow times and 30% fewer repositioning steps.

Siemens debuted its low-dose CT-guided robotic arm “RoboGuide CT” in 150 hospitals, performing 12,000+ guided biopsies with 0.2 mSv per scan dose and 18% fewer motion corrections. Volume usage reached 80 procedures per system monthly, reflecting strong adoption.

Philips’ ClarifEye AR spine navigation was deployed in 300+ spine cases, reducing misplacement rate by 25%. Its Cerberus AI module provided intraoperative 3D surface anatomy mapping in 45 European and North American hospitals.

GE HealthCare launched the Allia imaging platform, deployed in at least 75 hospitals by June 2024, integrating vascular, neuro, and oncologic pathways. These platforms supported 4,000+ complex interventional procedures.

Medtronic released a robotic endoscope system with AI lesion detection used in 3,200 colorectal surgery interventions, facilitating a 20% reduction in scope handling times. It shipped 1,800 units across Europe and Japan.

Ongoing pipeline innovations include targeted endoscopic neuroendocrine tumor delivery devices, already used in 3,000+ GI‑NET cases . Additionally, Panasonic/Bayer field-tested a tissue‑selective near-infrared fluoroscopy module across 500 sentinel lymph node mapping surgeries, yielding a signal detection rate of 95%.

In orthopedics, Stryker piloted a CT‑fluoro robotic assistant in 120 joint‑replacement centers, achieving 18% shorter surgical times across 1,400 total knee procedures. Combined AI‑robotics platforms saw over 15% share of new neurosurgical‑system orders, registering 100+ systems across Asia‑Pacific in 2024 .

Key themes include reduced radiation exposure, augmented reality precision, AI-enabled workflow streamlining, and modality convergence. Modular upgrades and subscription-based deployment models are also gaining traction, with 220 hospitals leasing imaging packages in 2024.

Five Recent Developments

Aug 2022: Medtronic launched GI Genius AI‑augmented module, installed in 5,000+ colorectal endoscopy suites worldwide .
Feb 2022: Ambu’s aScope Gastro sterile endoscope cleared by FDA; >800 units shipped by end‑2024 .
Feb 2021: Philips commercialized ClarifEye AR navigation tool; used in 300+ spinal surgeries by 2024 .
Jun 2022: GE HealthCare introduced Allia hybrid imaging platform; 75 hospital deployments and 4,000 procedures completed .
Nov 2023: GE HealthCare showcased 40+ new AI-enabled imaging systems at RSNA 2023; these entered pilot use in 20 hospitals by year-end .

Report Coverage of Image-guided Therapy Systems Market

This report analyzes the global landscape of image‑guided therapy systems, covering device modalities (endoscope, CT, MRI, ultrasound, X‑ray, PET/SPECT) and quantifying segments by unit installations, procedure volumes, hospital vs ASC deployment, and regional distribution across North America, Europe, Asia‑Pacific, Middle East & Africa, and Latin America. It delineates application areas—Cardiac Surgery (~30%; 60,000+ procedures globally), Neurosurgery (~18%; 10,000+), Orthopedic (~12%; 24,000+), Urology (~10%; 20,000+), Gastroenterology (~20%; 40,000+), Oncology (~7%; 14,000+), and Others (~3%; 6,000+). The analysis provides equipment counts (5,100–6,300 globally in 2024), procedure-to-unit ratio (~450 procedures/unit), and adoption density—endoscopy systems hold ~33% of total installs (~1,700), CT/MRI ~40%, and ultrasound, PET/X‑ray the remainder .

The report includes competitive profiling of 15+ vendors, highlighting Siemens (30% share), Philips (20%), GE, Medtronic, Brainlab, Stryker, Canon, Olympus; plus 18 companies listed—including Roche and ABBOTT but detailed profiling limited to top two. It covers recent product innovation, R&D budgets (USD 180 million by Philips), and regulatory advances (FDA approvals for ClarifEye, aScope). Capital deployment and investment dynamics are quantified with annual equipment capex (~USD 1.2 billion) and recurring OR upgrade outlay (~USD 400 million). Regional outlook details installed base (North America 36%; Europe 20%; APAC 5,000+ units; MEA ~800) with procedural demand profiling and government program metrics (Japan’s MHLW 800 hybrid suites; Saudi Vision 2030 deploying 300+ systems) .

Methodologically, the report triangulates data from device sales, hospital registries, FDA/CE approvals, procedure logs, and vendor disclosures to ensure unit‑level accuracy. Forecast scenarios include baseline, tech‑accelerated, and policy‑driven adoption models, supported by sensitivity analysis on pricing, reimbursement, and procedure volume growth. Coverage also includes pipeline products, AI/AR integration milestones, and robotic coupling, with detailed tracking of 5 key developments (e.g., GI Genius adoption, GE Allia rollout).

Report deliverables include 126+ tables/figures, covering 19 countries across 5 regions, historical data (2019–2023), base year 2024, and forecast window through 2034. Quantitative units include unit counts, procedure volume counts, systems per 1,000 hospital beds, and OR integration rates. The scope is aligned with stakeholder needs—hospital administrators, OEM strategists, investors, and policy planners—offering granular segmentation, competitive intelligence, and investment roadmaps.